Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Fish and Richardson
Julphar
Moodys
Federal Trade Commission
Healthtrust
Cerilliant
Fuji
Colorcon
Chubb

Generated: October 20, 2017

DrugPatentWatch Database Preview

ORTHO EVRA Drug Profile

« Back to Dashboard

What is the patent landscape for Ortho Evra, and what generic Ortho Evra alternatives are available?

Ortho Evra is a drug marketed by Janssen Pharms and is included in one NDA.

The generic ingredient in ORTHO EVRA is ethinyl estradiol; norelgestromin. There are twenty-six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norelgestromin profile page.

Summary for Tradename: ORTHO EVRA

US Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list8
Clinical Trials: see list71
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ORTHO EVRA at DailyMed

Pharmacology for Tradename: ORTHO EVRA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen Pharms
ORTHO EVRA
ethinyl estradiol; norelgestromin
FILM, EXTENDED RELEASE;TRANSDERMAL021180-001Nov 20, 2001DISCNYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ORTHO EVRA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Janssen Pharms
ORTHO EVRA
ethinyl estradiol; norelgestromin
FILM, EXTENDED RELEASE;TRANSDERMAL021180-001Nov 20, 2001► Subscribe► Subscribe
Janssen Pharms
ORTHO EVRA
ethinyl estradiol; norelgestromin
FILM, EXTENDED RELEASE;TRANSDERMAL021180-001Nov 20, 2001► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for ORTHO EVRA

Drugname Dosage Strength RLD Submissiondate
norelgestromin and ethinyl estradiolTransdermal System0.15 mg/0.02 mg per 24 hoursOrtho Evra3/22/2007
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Chinese Patent Office
Queensland Health
Johnson and Johnson
Cantor Fitzgerald
Citi
Moodys
Mallinckrodt
UBS
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot